Bayer, EDB to fund S$30m regional disease research
Effort will deepen cancer research and expand into heart and eye diseases
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
PHARMACEUTICAL giant Bayer HealthCare and the Singapore Economic Development Board (EDB) will jointly foster translational and clinical research for diseases prevalent in Asia over the next five years, they announced at a launch ceremony on Wednesday.
EDB will facilitate collaborations between Bayer HealthCare and its partner institutes - including SingHealth Duke-NUS Academic Medical Centre and National University Health System (NUHS) - to increase existing research efforts in cancer treatment, and expand into the research of heart and eye diseases.
Copyright SPH Media. All rights reserved.
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Beijing’s calculated silence on the Iran war
DPM Gan warns of 3 structural shifts to the global system that will bring greater challenges – and opportunities
